Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development

RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the appointment of Andrew Beelen, MD, as Vice President of Clinical Development. Dr. Beelen will be responsible for progressing the clinical development of INX-315 and brings a wealth of experience and expertise to this pivotal leadership role.

Dr. Beelen joins Incyclix Bio with over 20 years of experience in the pharmaceutical industry with a specialized background in developing oncology therapeutics. Most recently, Dr. Beelen was the Executive Director of Clinical Development at G1 Therapeutics, Inc., where he was responsible for leading the development of multiple clinical programs, including COSELA® (trilaciclib), a CDK4/6 inhibitor. He has also held leadership positions at Quintiles, Watson Laboratories, Myrexis, and GlaxoSmithKline. Throughout his career, Dr. Beelen has led clinical development activities across all phases of development and has provided leadership in regulatory interactions spanning IND to NDA.

“We are delighted to welcome Andy to the Incyclix team as Vice President of Clinical Development,” said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio. “Andy has a proven track record of successfully leading clinical and regulatory activities for novel oncology therapeutics at all stages of development. He joins our team at a critical period of growth as we rapidly progress INX-315 development for cancer patients with unmet medical needs.”

“I am thrilled to join the talented team at Incyclix Bio and leverage my expertise to help bring INX-315 to cancer patients in need of innovative treatment options,” said Dr. Beelen. “CDK2 is a well-validated precision oncology target that has historically eluded drug development efforts aimed at identifying CDK2 inhibitors with sufficient selectivity over other CDK family members. With the development of INX-315, Incyclix has broken through past barriers and identified a potent and selective CDK2 inhibitor with best-in-class potential.”

Dr. Beelen completed his fellowship in clinical pharmacology and residency in internal medicine at Dartmouth Hitchcock Medical Center. He received an MD from the State University of New York Upstate Medical University (SUNY Upstate) and earned a Bachelor of Science from the Albany College of Pharmacy. Dr. Beelen has authored numerous peer-reviewed publications and abstracts and serves on the industry advisory board of Eshelman Innovation at UNC.

About Incyclix Bio

Incyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development. For more information, visit incyclixbio.com.

Media Contact

Tony Plohoros
908-591-2839
tplohoros@6degreespr.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.